Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

378 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rare variants and survival of patients with idiopathic pulmonary fibrosis.
Alonso-Gonzalez A, Jáspez D, Lorenzo-Salazar JM, Ma SF, Strickland E, Mychaleckyj J, Kim JS, Huang Y, Adegunsoye A, Oldham JM, Steward I, Molyneaux PL, Maher TM, Wain LV, Allen RJ, Jenkins RG, Kropski JA, Yaspan B, Blackwell TS, Zhang D, Garcia CK, Martinez FJ, Noth I, Flores C. Alonso-Gonzalez A, et al. Among authors: maher tm. medRxiv [Preprint]. 2024 Oct 15:2024.10.12.24315151. doi: 10.1101/2024.10.12.24315151. medRxiv. 2024. PMID: 39484282 Free PMC article. Preprint.
Effects of nintedanib on circulating biomarkers of idiopathic pulmonary fibrosis.
Jenkins RG, Cottin V, Nishioka Y, Noth I, White ES, Ittrich C, Diefenbach C, Rohr KB, Selman M, Maher TM. Jenkins RG, et al. Among authors: maher tm. ERJ Open Res. 2024 Dec 16;10(6):00558-2023. doi: 10.1183/23120541.00558-2023. eCollection 2024 Nov. ERJ Open Res. 2024. PMID: 39687396 Free PMC article.
Design of CONQUEST, a novel, randomized, placebo-controlled, Phase 2b platform clinical trial to investigate new treatments for patients with early active systemic sclerosis with interstitial lung disease.
Khanna D, Evnin LB, Assassi S, Benton WW, Gordon G, Maslova K, Steffgen J, Maher TM. Khanna D, et al. Among authors: maher tm. J Scleroderma Relat Disord. 2024 Nov 5:23971983241278079. doi: 10.1177/23971983241278079. Online ahead of print. J Scleroderma Relat Disord. 2024. PMID: 39544897 Free PMC article.
Efficacy and Safety of Admilparant, an LPA1 Antagonist in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial.
Corte TJ, Behr J, Cottin V, Glassberg MK, Kreuter M, Martinez FJ, Ogura T, Suda T, Wijsenbeek M, Berkowitz E, Elpers B, Kim S, Watanabe H, Fischer A, Maher TM. Corte TJ, et al. Among authors: maher tm. Am J Respir Crit Care Med. 2024 Oct 11. doi: 10.1164/rccm.202405-0977OC. Online ahead of print. Am J Respir Crit Care Med. 2024. PMID: 39393084
378 results